The Report Guru

According to research report Perfusion Systems Market is expected to reach USD 1,198.8 Million by 2021 from USD 989.4 Million in 2016, at a CAGR of 3.9%. The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region. Read More : https://www.marketsandmarkets.com/PressReleases/perfusion-system.asp Major Market Developments: ·          In January 2015, Medtronic acquired Covidien plc. (Ireland), a manufacturer of healthcare products for use in clinical and home settings worldwide. This acquisition aims to strengthen Medtronic’s customer base and resolve healthcare challenges with constant product development and imbibing new technologies. ·          In October 2015, Sorin merged with Cyberonics Inc (US) to form a global medical technology company—LivaNova PLC (U.K.). ·          In February 2014, Sorin acquired Bioengineering Laboratories S.p.A. (BEL), a ma

Market growth factors The market for leukemia therapeutics is mainly driven by the high prevalence of the disease. Asia and Europe have high prevalence rates of leukemia, followed by North America, making these regions the key markets for therapeutics. Other factors driving the leukemia therapeutics market growth include the introduction of innovative therapies.                However, complexities in manufacturing serve as a key restraint to market growth. Companies in this market are required to comply with stringent regulations during product manufacturing and testing, which considerably slows the introduction of new products in the market.                             What experts says about the growth of this market? According to the new market research report the leukemia therapeutics market is projected to reach USD 17.1 billion by 2024 from USD 12.3 billion in 2019, at a CAGR of 6.8% during the forecast period. Download Brochure: https://www.marketsandmarket

According to research report the life science analytics market is projected to reach USD 33.2 billion by 2024 from USD 19.3 billion in 2019, at a CAGR of 11.5% during the forecast period. Growth in this market is mainly driven by technological advancements, big data in the life science industry, growing adoption of analytics solutions in clinical trials, increasing adoption of analytics for sales and marketing applications, need for improved data standardization, increasing prevalence of chronic diseases, growing pressure to curb healthcare spending, and the need for improved patient outcomes. On the other hand, high implementation costs are expected to restrain the growth of this market to a certain extent Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174990653 The life science analytics market has been segmented on the basis of type, component, delivery model, application, end user, and region. Based on type, the life science analyt

Cerner Corporation (U.S.) is one of the largest players in the market. In order to remain competitive, the company primarily adopted growth strategies such as agreements, collaborations, and partnerships for enhancing its presence in the market. For instance, in 2016, The UAE Ministry of Health and Prevention (MOHAP) renewed its strategic agreement with Cerner Corporation. Similarly, in 2015, Truman Medical Centers (TMC) (U.S.) partnered with Cerner Corporation to leverage Cerner’s health care information technology (IT) solutions. Market Size - According to research the research report Ambulatory EHR Market is expected to reach USD 5.20 billion by 2021 from USD 3.92 billion in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021). The Ambulatory EHR market is dominated by Cerner Corporation (U.S.) and McKesson Corporation (U.S.) Read More - https://www.marketsandmarkets.com/PressReleases/ambulatory-ehr.asp Allscripts Healthcare Solutions, Inc. (U.S.) is among the l

According to the new market research report Prosthetic Heart Valve Market is projected to reach USD 8.86 Billion by 2022 from USD 4.84 Billion in 2017, at a CAGR of 12.9% during the forecast period. The key factors driving the growth of this market include the rising geriatric population and the subsequent growth in the prevalence of HVD, regulatory approvals for new and advanced prosthetic heart valves, increasing government funding for heart valve research, rising awareness about HVD, and favorable reimbursement scenario for prosthetic heart valves. Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=245407958 Medtronic plc (Ireland), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K.), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK Healthcare Limited (India), Colibri Heart Valve, LLC (U.S.)

The increasing prevalence of cancer, rising government support for research on cancer biomarkers, growing use of biomarkers in drug discovery and development, and increasing use of biomarker tests for diagnostic purposes are the major factors that are driving the growth of this market. Market Size - According to research report the global cancer biomarkers market to reach USD 20.4 billion by 2022. and is estimated to grow at a CAGR of 12.2% during the forecast period. The APAC region is projected to register the highest CAGR during the forecast period. The APAC market for cancer biomarkers has witnessed significant growth due to increasing demand for better healthcare services in developing economies such as India and China. Read More: https://www.marketsandmarkets.com/PressReleases/oncology-biomarkers-market.asp In this report, the market is segmented into biomarker type, cancer type, profiling technology, application, and region. • On the basis of biomarker type, the ca